Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials.

ABSTRACT:

Background

Individualized prediction of treatment response may improve the value proposition of advanced treatment options in severe asthma. This study aimed to investigate the combined capacity of patient characteristics in predicting treatment response to mepolizumab in patients with severe asthma.

Methods

Patient-level data were pooled from two multinational phase 3 trials of mepolizumab in severe eosinophilic asthma. We fitted penalized regression models to quantify reductions in the rate of severe exacerbations and the 5-item Asthma Control Questionnaire (ACQ5) score. The capacity of 15 covariates towards predicting treatment response was quantified by the Gini index (measuring disparities in treatment benefit) as well as observed treatment benefit within the quintiles

SUBMITTER: Chen W 

PROVIDER: S-EPMC10155396 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature